NDA 215431 · Axsome
Symbravo
Meloxicam, Rizatriptan Benzoate · Oral · Nonsteroidal Anti-inflammatory Drug
Last checked: Nov 19, 2026Latest source record: Jan 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jan 30, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
142
48 Phase 3, 10 recruiting
FAERS reports
36
3 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Risk Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings & Precautions (5.1) ] . SYMBRAVO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) , Warnings & Precautions (5.1) ] . Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI...
What it is approved for
From the label in effect Oct 8, 2026.
SYMBRAVO is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use SYMBRAVO should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with SYMBRAVO, the diagnosis of migraine should be reconsidered before SYMBRAVO is administered to treat any subsequent attacks. SYMBRAVO is not indicated for the preventive treatment of migraine attacks. SYMBRAVO is not indicated for the treatment of cluster headache. SYMBRAVO is a combination of meloxicam (an NSAID) and rizatriptan (a serotonin (5-HT) 1B/1D receptor agonist (triptan)), indicated for the acute treatment of migraine with or without aura in adults ( 1 ). Limitations of Use SYMBRAVO should only be used where a clear diagnosis of migraine has been established ( 1 ). SYMBRAVO is not indicated for the preventive treatment of migraine ( 1 ). SYMBRAVO is not indicated for the treatment of cluster headache ( 1 ).
Mechanism: SYMBRAVO contains meloxicam and rizatriptan. Meloxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because meloxicam...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 30, 2025 Original approval · Type 4 - New Combination LabelMedication GuideLetter
1 products under this application
- SYMBRAVO · MELOXICAM 20MG; RIZATRIPTAN BENZOATE EQ 10MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Meloxicam" as an intervention, any sponsor and status, largest first.
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- Maximizing Outcomes in Treating Acute MigrainePivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT03896009 · 1,594 participants · Start Mar 4, 2019 · Primary completion Dec 10, 2019
Drug: AXS-07 (MoSEIC meloxicam and rizatriptan); Meloxicam and 2 more · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 85 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT02183064 · 1,309 participants · Start Oct 1998 · Primary completion Nov 2000
Drug: Meloxicam; NSAID · For: Osteoarthritis
- A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid ArthritisPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00042068 · 1,000 participants · Start Jun 2002
Drug: Meloxicam · For: Arthritis, Rheumatoid
Sites: Huntsville, Alabama; Montgomery, Alabama; Anchorage, Alaska · 153 sites in all
- Evaluation of N1539 Following Major SurgeryPivotal-lookingCompleted
Baudax BioIndustry
NCT02720692 · 722 participants · Start Mar 2016 · Primary completion Mar 2017
Drug: N1539; Intravenous Placebo · For: Pain, Post-operative
Sites: Florence, Alabama; Montgomery, Alabama; Sheffield, Alabama · 32 sites in all
- Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)Pivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04068051 · 706 participants · Start Jul 6, 2019 · Primary completion Sep 22, 2020
Drug: AXS-07 · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 51 sites in all
- Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or HipPivotal-lookingCompleted
Iroko Pharmaceuticals, LLCIndustry
NCT01801735 · 600 participants · Start Mar 2013 · Primary completion Jun 2014
Drug: Meloxicam Test Capsules · For: Osteoarthritis
Sites: Birmingham, Alabama; Phoenix, Arizona; Carmichael, California · 40 sites in all
- Opioid-Free Orthopaedic SurgeryPivotal-lookingCompleted
OrthoCarolina Research Institute, Inc.Academic, hospital or other
NCT04176783 · 511 participants · Start Mar 26, 2018 · Primary completion Jul 21, 2021
Drug: Opioids; Opioid-Free · For: Pain Management
Sites: Charlotte, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness5
- drug ineffective5
- fatigue3
- feeling abnormal3
- headache3
- nausea3
- palpitations3
- asthenia2
- burning sensation2
- flushing2
- paraesthesia2
- tachycardia2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 12 |
| 2026 | 24 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nonsteroidal Anti-Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
Tawfik AG, Gomez-Lumbreras A, Del Fiol G, et al. · Clin Pharmacol Ther 2026 · Systematic Review, Meta-Analysis
- Efficacy of tramadol for postoperative pain management in dogs: systematic review and meta-analysis.
Donati PA, Tarragona L, Franco JVA, et al. · Vet Anaesth Analg 2021 · Meta-Analysis, Systematic Review
- Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project).
Castellsague J, Riera-Guardia N, Calingaert B, et al. · Drug Saf 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Bioequivalence of Meloxicam Nanocrystal Injection in Healthy Chinese Volunteers.
Hu S, Liu X, Wan Q, et al. · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer.
Hong S, Ju JH, Lee SH, et al. · Gut Liver 2025 · Randomized Controlled Trial, Multicenter Study
- Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews.
Moore RA, Derry S, Aldington D, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Axsome
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.